Unilife took another big step this week, signing a long-term contract agreement with generics maker Hikma Pharmaceuticals to use Unilife's injectable technology and netting up to $40 million in the process.
Actinium Pharmaceuticals spoke with the FDA last week and is now planning to roll out a Phase III pivotal trial of its targeted immunotherapeutic cancer treatment using its radioisotope delivery platform.
New Jersey device outfit Svelte Medical Systems finished enrolling patients in a pivotal study of its Integrated Delivery System (IDS) drug-eluting coronary stent, comparing it with Medtronic's Resolute Integrity drug-eluting stent.
Researchers at the Icahn School of Medicine at Mount Sinai Hospital used a virus to deliver genes directly to the heart to reverse heart failure, shrinking an enlarged heart and improving its function.
To get through a dense jungle, you'll need to clear a path. Similarly, to get past a thick network of scaffolding that often prevents drugs from reaching cancer cells, UCLA researchers have developed nanoparticles capable of clearing a path for drugs to pass through to a tumor.
FierceDrugDelivery spoke with the prolific drug delivery expert about the field's future, regarding nanotechnology in particular, as well as some of the projects Langer's lab and various business ventures are undertaking currently to make next-gen nanomedicine a reality.
Israel's Oramed won a patent from the European Union for its oral insulin pill, giving the Jerusalem company a potential foothold in the diabetes market estimated to be worth about $14 billion by 2017, according to analysts.
A team of researchers from Nottingham University in the U.K. have repurposed a bone-healing polymer to achieve something very different: delivery of cancer drugs to tumors in the brain after surgery.
Liquidia Technologies launched a new company this week with $25 million in Series A funding aimed at developing an extended-release glaucoma treatment that could last for several months after one injection.
Researchers in the U.K. are taking a hard line on the delivery of biologics to treat a variety of diseases using new delivery methods to get the large molecules safely past the cell membrane.
A small patch that delivers DNA-loaded nanoparticles may be the next step in bone regeneration, offering a new option for patients currently receiving repeated, painful injections.
To get treatments past one P-glycoprotein on the cell's surface, researchers in Germany have developed nanoparticles made of carbon that can overcome this type of drug resistance.
Injectable drug delivery specialist Unilife joined forces with AstraZeneca's MedImmune this week to use Unilife's wearable devices with MedImmune's line of large molecules, putting both companies on the leading edge of a potentially profitable market.
RNA delivery specialist Arrowead Research heralded new data supporting its genetic treatment for hepatitis B, which makes use of the company's polymer-based method for effectively getting RNAi to the nucleus. And its immunological response offers what could be a "functional cure" for the disease.
Danish diabetes care giant Novo Nordisk won FDA approval this week for two of its FlexTouch prefilled insulin pens, the NovoLog and Levemir.
If you want to cripple cancer cells, go straight for their power source, according to researchers at MIT and the University of Toronto. The scientists have developed a delivery method for the cancer drug cisplatin that sends it straight to the energy-producing mitochondria of the offending cells.
To deliver a genetic kill switch to a particularly aggressive brain tumor, researchers at Northwestern University are turning to gold nanoparticles designed to maneuver their way into the cancer cells.
A team from IBM Research and the Institute of Bioengineering and Nanotechnology in Singapore have designed a Vitamin E-based hydrogel that can release Roche's cancer antibody Herceptin under the skin for several weeks.
MIT professor and biotech entrepreneur Robert Langer and colleagues have created a synthetic version of the natural high-density lipoprotein--or "good cholesterol"--for use in drug delivery to treat cardiovascular diseases such as atherosclerosis.
Researchers at the University of New South Wales have developed iron oxide nanoparticles capable of both delivering cancer drugs and precisely measuring their release in real time.